Pharma: Clinic Roundup
Friday, August 23, 2013
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said favorable results from two Phase III studies, Gemini I and Gemini II, evaluating the humanized monoclonal antibody vedolizumab for moderately to severely active ulcerative colitis and Crohn's disease were published in the Aug. 22, 2013, issue of the New England Journal of Medicine.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.